Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Sarcoma
- Sarcoma Metastatic
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 16 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04076579
- Collaborators
- Janssen Scientific Affairs, LLC
- AstraZeneca
- Investigators
- Principal Investigator: Rashmi Chugh, M.D. University of Michigan Rogel Cancer Center